
ADVM
Adverum Biotechnologies Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.740
Open
2.680
VWAP
2.69
Vol
148.63K
Mkt Cap
55.78M
Low
2.615
Amount
399.73K
EV/EBITDA(TTM)
--
Total Shares
20.76M
EV
-26.68M
EV/OCF(TTM)
--
P/S(TTM)
--
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. It discovers and develops gene therapy product candidates that provide durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD). Its other partnered programs include BGTF-027 (AAV.7m8-L-opsin), a gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.
Show More
5 Analyst Rating

474.16% Upside
Wall Street analysts forecast ADVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADVM is 15.33 USD with a low forecast of 4.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy

474.16% Upside
Current: 2.670

Low
4.00
Averages
15.33
High
30.00

474.16% Upside
Current: 2.670

Low
4.00
Averages
15.33
High
30.00
Mizuho
Outperform
to
NULL
downgrade
$16 -> $12
2025-06-26
Reason
Mizuho
Price Target
$16 -> $12
2025-06-26
downgrade
Outperform
to
NULL
Reason
RBC Capital
Sector Perform
maintain
$5 -> $4
2025-05-15
Reason
RBC Capital
Price Target
$5 -> $4
2025-05-15
maintain
Sector Perform
Reason
RBC Capital lowered the firm's price target on Adverum Biotechnologies to $4 from $5 and keeps a Sector Perform rating on the shares after its Q1 results. The company's first US-based wet AMD pivotal study is underway and is enrolling both treatment-experienced and treatment-naive patients, though the firm's reduced price target reflects Adverum's financial overhang as it remains on the sidelines pending further de-risking, the analyst tells investors in a research note.
Chardan Capital
Daniil Gataulin
Strong Buy
Maintains
$40 → $33
2025-04-17
Reason
Chardan Capital
Daniil Gataulin
Price Target
$40 → $33
2025-04-17
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$30
2025-04-16
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$30
2025-04-16
Reiterates
Strong Buy
Reason
RBC Capital
Luca Issi
Hold
Maintains
$10 → $5
2025-04-16
Reason
RBC Capital
Luca Issi
Price Target
$10 → $5
2025-04-16
Maintains
Hold
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$30
2024-11-19
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$30
2024-11-19
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Adverum Biotechnologies Inc (ADVM.O) is -0.55, compared to its 5-year average forward P/E of -7.59. For a more detailed relative valuation and DCF analysis to assess Adverum Biotechnologies Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-7.59
Current PE
-0.55
Overvalued PE
11.46
Undervalued PE
-26.64
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-1.12
Current EV/EBITDA
-0.33
Overvalued EV/EBITDA
1.30
Undervalued EV/EBITDA
-3.54
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
524.16
Current PS
4.41
Overvalued PS
1611.22
Undervalued PS
-562.91
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+65.15%
-48.22M
Operating Profit
FY2025Q1
YoY :
+73.20%
-47.02M
Net Income after Tax
FY2025Q1
YoY :
+36.36%
-2.25
EPS - Diluted
FY2025Q1
YoY :
+84.23%
-42.99M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
26.0K
USD
3
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
10
2.1M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
211.9K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
53.1K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
26.0K
USD
3
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
10
2.1M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ADVM News & Events
Events Timeline
2025-05-14 (ET)
2025-05-14
16:33:56
Adverum Biotechnologies reports Q1 EPS ($2.25), consensus ($1.97)

2025-04-15 (ET)
2025-04-15
07:44:15
Adverum Biotechnologies announces anticipated milestones

2025-04-15
07:43:38
Adverum Biotechnologies sees cash runway into 2H25

Sign Up For More Events
Sign Up For More Events
News
1.0
07-14GlobenewswirePresenting on Emerging Growth Conference 84 Day 1 on July 16; Register to live stream
9.5
05-14NewsfilterAdverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights
7.0
05-09GlobenewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Sign Up For More News
People Also Watch

LTBR
Lightbridge Corp
14.950
USD
+8.02%

DTSQ
DT Cloud Star Acquisition Corp
10.471
USD
+0.59%

GRWG
GrowGeneration Corp
1.110
USD
-7.50%

SIFY
Sify Technologies Ltd
5.600
USD
-4.27%

COYA
Coya Therapeutics Inc
6.720
USD
+10.71%

OPRX
OptimizeRx Corp
13.940
USD
+1.23%

PWUP
PowerUp Acquisition Corp
8.600
USD
-17.42%

MNOV
MediciNova Inc
1.240
USD
-1.59%

INVE
Identiv Inc
3.750
USD
+4.46%

TRX
TRX Gold Corp
0.381
USD
+2.14%
FAQ

What is Adverum Biotechnologies Inc (ADVM) stock price today?
The current price of ADVM is 2.67 USD — it has decreased -1.11 % in the last trading day.

What is Adverum Biotechnologies Inc (ADVM)'s business?

What is the price predicton of ADVM Stock?

What is Adverum Biotechnologies Inc (ADVM)'s revenue for the last quarter?

What is Adverum Biotechnologies Inc (ADVM)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Adverum Biotechnologies Inc (ADVM)'s fundamentals?

How many employees does Adverum Biotechnologies Inc (ADVM). have?
